Note: All questions come from attendees of the 2013 Patient Education Symposium.
Q: What are the anticipated gains resulting from stem cell infusion?
Tisch MS News
Tune in to The Dr. Oz Show this Thursday, December 12th to see Dr. Sadiq as a featured guest along with his patient Richard Cohen and Richard's spouse Meredith Vieira. Richard and Meredith will be discussing living with MS and their hopes for our recently approved FDA Phase I Stem Cell Clinical Trial!
Dr. Steven A. Goldman, MD, PhD, Co-Director of the Center for Translational Medicine and Professor in the Departments of Neurology and Neurosurgery at the University of Rochester School of Medicine and Dentistry, delivered the Grand Rounds lecture for December 4, 2013. Dr. Goldman's presentation was entitled "Progenitor Cell-Based Therapy for Secondary Progressive Multiple Sclerosis."
Tisch MS Research Center of New York would like to advise patients and other interested parties that we will be closing at 2pm on Wednesday, November 27, and reopening on Monday, December 2, in observance of the Thanksgiving holiday.
Tisch MSRCNY welcomed almost 1,000 guests on Sunday, October 13, 2013 to the New York Hilton. We would like to thank our patients and supporters for making this a truly momentous event!
The title of Dr. Sadiq’s talk, “What Does This Study Mean For Me?” signified an opportunity to answer many questions about our recent FDA Approval to begin a Phase I Clinical Stem Cell Trial using autologous stem cells. First and foremost, if you would like to express interest in participation in this study, you must speak to your IMSMP neurologist.
Multiple Sclerosis Journal has selected the recent Tisch MS publication "Cerebrospinal fluid fetuin-A is a biomarker of active multiple sclerosis," co-authored by Violaine Harris, PhD, and Saud Sadiq, MD, among others, as its cover article for October 2013.
Ricki Lewis, Ph.D., filed a report for the Multiple Sclerosis Discovery Forum on FDA approval for the upcoming clinical trial of MSC-NPs at the Tisch MS Research Center of New York. Lewis quotes multiple outside experts alongside Saud Sadiq, M.D., director of Tisch MS, on the science behind the trial and on the outstanding questions regarding MSC-NPs and MSC-NP therapy still unresolved in current research.
The stem cell research division of the Tisch MS Research Center of New York proudly announces Food and Drug Administration (FDA) approval of autologous, mesenchymal stem cell-derived neural progenitor cells (MSC-NPs) as an Investigational New Drug (IND) for an open label, phase I clinical trial in the treatment of multiple sclerosis.
A Research team lead by Violaine Harris, Ph.D., at the Tisch MS Research Center of New York, has just published findings on a new method of measuring disease activity in patients with multiple sclerosis (MS) (Harris, et al, Cerebrospinal fluid fetuin-A is a biomarker of active multiple sclerosis, Multiple Sclerosis Journal, Epub: 2/25/2013 doi: 10.1177/1352458513477923 ahead of print). This important biomarker discovery is based on spinal fluid measurement of Fetuin
Tisch MS Research Center of New York has formally submitted a response to the Food and Drug Administration’s (FDA) clinical hold on our proposed Phase I trial of Mesenchymal Stem Cell-Derived Neural Progenitors in the treatment of multiple sclerosis. Per agency rules, this submission necessitates a reply from the FDA within 30 days of filing. Within another 30 days of the FDA’s reply, we expect to schedule a meeting in order to discuss the FDA’s comments on our submission.
Pages
